Boston Scientific Corporation $BSX Stake Boosted by Consolidated Planning Corp

Consolidated Planning Corp increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 2.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,313 shares of the medical equipment provider’s stock after purchasing an additional 1,133 shares during the quarter. Consolidated Planning Corp’s holdings in Boston Scientific were worth $5,404,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Robeco Institutional Asset Management B.V. increased its position in Boston Scientific by 31.6% in the second quarter. Robeco Institutional Asset Management B.V. now owns 3,145,777 shares of the medical equipment provider’s stock worth $337,888,000 after buying an additional 756,199 shares during the period. BSW Wealth Partners boosted its stake in Boston Scientific by 2.2% during the second quarter. BSW Wealth Partners now owns 8,667 shares of the medical equipment provider’s stock valued at $931,000 after buying an additional 188 shares in the last quarter. Woodward Diversified Capital LLC bought a new position in Boston Scientific during the second quarter valued at about $205,000. Vigilare Wealth Management bought a new position in Boston Scientific during the second quarter valued at about $558,000. Finally, Deltec Asset Management LLC boosted its position in shares of Boston Scientific by 335.4% in the 2nd quarter. Deltec Asset Management LLC now owns 28,300 shares of the medical equipment provider’s stock valued at $3,040,000 after purchasing an additional 21,800 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 1.9%

Shares of NYSE BSX opened at $95.78 on Thursday. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The firm has a market capitalization of $141.91 billion, a PE ratio of 57.01, a PEG ratio of 2.35 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The business has a 50-day moving average price of $103.30 and a two-hundred day moving average price of $102.08.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the company posted $0.62 EPS. The business’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on BSX. Canaccord Genuity Group increased their price target on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday. Truist Financial increased their price target on Boston Scientific from $125.00 to $129.00 and gave the company a “buy” rating in a research report on Wednesday. Robert W. Baird increased their price target on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday. UBS Group increased their price target on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Finally, Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $120.67.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.